A new international clinical trial led by the National Cancer Center Singapore is reporting that three years of aspirin following standard adjuvant therapy for high-risk Dukes’ B and C colorectal cancer did not yield a significant advantage in preventing disease recurrence.
Go to Source
https://medicalxpress.com/rss-feed/